NOTE: As provided in LFC policy, this report is intended only for use by the standing finance committees of the legislature. The Legislative Finance Committee does not assume responsibility for the accuracy of the information in this report when used in any other situation.

Only the most recent FIR version (in HTML & Adobe PDF formats) is available on the Legislative Website. The Adobe PDF version includes all attachments, whereas the HTML version does not. Previously issued FIRs and attachments may be obtained from the LFC's office in Suite 101 of the State Capitol Building North.

FISCAL IMPACT REPORT

SPONSOR:	Altamirano	DATE TYPED:	1/22/02	НВ	
SHORT TITLE	E: Prostate Cancer Tas	k Force		SB	SJM8
			ANAL	YST:	Esquibel

APPROPRIATION

Appropriation Contained		Estimated Additional Impact		Recurring or Non-Rec	Fund Affected
FY02	FY03	FY02	FY03		
	N/A				

(Parenthesis () Indicate Expenditure Decreases)

SOURCES OF INFORMATION

Responses Received From

Department of Health (DOH)

SUMMARY

Synopsis of Bill

Senate Joint Memorial 8 resolves that DOH create a task force that includes representatives from the American Cancer Society, Prostate Cancer Support Association of New Mexico, health care practitioners and others to develop a plan to implement a program of education, awareness and support groups concerning the issue of prostate cancer in New Mexico. The task force would present its plan and recommendations to the appropriate legislative committee by October 2002.

Significant Issues

Each year in New Mexico, over 1,000 men are diagnosed with prostate cancer, and almost 200 die of the disease. Prostate cancer is the most frequently diagnosed cancer in men and the second leading cause of cancer death in the U.S.

FISCAL IMPLICATIONS

DOH reports it currently contracts with the Prostate Cancer Support Association (PCSA) of New Mexico in the amount of \$50.0, primarily for support services to men who have been diagnosed with prostate cancer. PCSA is also active in seeking ways to educate men about prostate cancer risk reduction, screening and treatment.

RAE/sb